iBio Q2 EPS Forecast Decreased by Brookline Capital Markets

Key Points

• Brookline Capital Markets cut iBio’s Q2 2027 EPS forecast to a loss of $0.08 per share from a previous estimate of $0.07, while projecting a $0.31 loss for full-year 2027.
• iBio’s latest quarterly results beat expectations, reporting a $0.04-per-share loss versus the $0.07 consensus estimate.
• Analyst sentiment remains broadly positive, with a consensus “Buy” rating and an average $5.00 price target, despite the stock opening at $1.26 and having a one-year range of $0.77 to $3.82.

iBio, Inc. (NASDAQ:IBIO - Free Report) - Investment analysts at Brookline Capital Markets lowered their Q2 2027 earnings per share (EPS) estimates for iBio in a note issued to investors on Sunday, August 30th. Brookline Capital Markets analyst K. Dolliver now expects that the company will post earnings of ($0.08) per share for the quarter, down from their previous estimate of ($0.07). The consensus estimate for iBio's current full-year earnings is ($0.30) per share. Brookline Capital Markets also issued estimates for iBio's Q3 2027 earnings at ($0.08) EPS, Q4 2027 earnings at ($0.08) EPS and FY2027 earnings at ($0.31) EPS.

iBio (NASDAQ:IBIO - Get Free Report) last released its earnings results on Friday, August 28th. The company reported ($0.04) EPS for the quarter, topping analysts' consensus estimates of ($0.07) by $0.03.

A number of other analysts have also weighed in on IBIO. Raymond James Financial assumed coverage on shares of iBio in a research note on Monday, June 8th. They set an "outperform" rating and a $5.00 price objective for the company. Wall Street Zen downgraded shares of iBio from a "hold" rating to a "sell" rating in a research note on Sunday, August 23rd. Chardan Capital reiterated a "buy" rating and set a $5.00 price target on shares of iBio in a report on Thursday, July 2nd. Weiss Ratings reissued a "sell (d-)" rating on shares of iBio in a research report on Wednesday, June 24th. Finally, B. Riley Financial initiated coverage on shares of iBio in a research report on Friday, June 5th. They set a "buy" rating and a $6.00 price target for the company. Three analysts have rated the stock with a Strong Buy rating, four have assigned a Buy rating and one has given a Sell rating to the stock. According to MarketBeat, the company has a consensus rating of "Buy" and an average price target of $5.00.

iBio Price Performance

IBIO opened at $1.26 on Wednesday. The firm has a market cap of $62.60 million, a PE ratio of -3.71 and a beta of 1.29. The stock has a 50-day moving average price of $1.47 and a 200-day moving average price of $1.82. iBio has a 1 year low of $0.77 and a 1 year high of $3.82.

Hedge Funds Weigh In On iBio

A number of hedge funds have recently bought and sold shares of IBIO. XTX Topco Ltd bought a new position in iBio during the 4th quarter valued at about $71,000. Persistent Asset Partners Ltd bought a new stake in shares of iBio in the fourth quarter worth approximately $76,000. Susquehanna International Group LLP bought a new stake in shares of iBio in the third quarter worth approximately $37,000. Headlands Technologies LLC raised its holdings in shares of iBio by 333.0% during the second quarter. Headlands Technologies LLC now owns 47,413 shares of the company's stock valued at $83,000 after purchasing an additional 36,463 shares during the last quarter. Finally, Cubist Systematic Strategies LLC purchased a new position in shares of iBio during the first quarter valued at approximately $224,000. Hedge funds and other institutional investors own 7.90% of the company's stock.

iBio Company Profile

iBio, Inc, a biotechnology company, provides contract development and manufacturing services to collaborators and third-party customers in the United States. The company operates in two segments: Biopharmaceuticals and Bioprocessing. Its lead therapeutic candidate is IBIO-100 that is being advanced for investigational new drug development for the treatment of systemic scleroderma and idiopathic pulmonary fibrosis. The company is also developing vaccine candidates comprising IBIO-200 and IBIO-201, which are in preclinical development for the prevention of severe acute respiratory syndrome coronavirus 2; and IBIO-400 for the treatment of classical swine fever.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source